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Peroxisome proliferator activated receptor γ (PPARγ) agonists are widely used in the treatment of type 2 diabetes. Side eﬀects of
drug treatment include both ﬂuid retention and a lowering of blood pressure. Data from animal and human studies suggest that
theseeﬀectsarise,atleastinpart,fromdrug-inducedchangesinthekidney.Inordertocapitalizeonthepositiveaspect(loweringof
blood pressure) and exclude the negative one (ﬂuid retention), it is necessary to understand the mechanisms of action underlying
each of the eﬀects. When interpreted with known physiological principles, current hypotheses regarding potential mechanisms
produce enigmas that are diﬃcult to resolve. This paper is a summary of the current understanding of PPARγ agonist eﬀects on
both blood pressure and ﬂuid retention from a renal perspective and concludes with the newest studies that suggest alternative
pathways within the kidney that could contribute to the observed drug-induced eﬀects.
1.Introduction
PPARγ agonists, also called thiazolidinediones (TZDs), are
widely used as insulin-sensitizing agents in the treatment of
type 2 diabetes. One unanticipated, and poorly understood,
side eﬀect of the TZDs is a lowering of blood pressure.
In the vast majority of patients treated with these drugs,
the change in blood pressure per se can be viewed as
a positive consequence of drug therapy. Statistically the
classic type 2 diabetic patient has increased blood pressure
that is treated by pharmaceutical intervention. Indeed, this
beneﬁcial property as well as positive eﬀects on lipid proﬁles
and inﬂammatory responses has prompted the suggestion
that this class of drugs might be useful in treating metabolic
syndrome, a prediabetic state that is reaching epidemic
proportions in industrialized societies [1, 2].
However, treatment with PPARγ agonists is not without
negative side eﬀects. Particularly noteworthy when consid-
ering using TZDs to treat overweight or obese patients
is the propensity for these drugs to cause weight gain.
The weight gain is multifactorial and includes a positive
eﬀect on adipogenesis [3] and a diuretic-resistant ﬂuid
retention [4, 5]. As with the eﬀect on blood pressure,
the physiological mechanisms responsible for ﬂuid retention
are poorly understood.
This paper examines the positive (lowering of blood
pressure) and the negative (ﬂuid retention) side eﬀects of
TZD treatment from a renal perspective. An important con-
sideration for the development of drugs to treat metabolic
syndrome is the question of whether the beneﬁcial side eﬀect
can be dissociated from the negative action. Unfortunately,
at this point one can only outline the issues—the answers
await further experimentation to elucidate the mechanisms
of action involved in these side eﬀects.
2. Fluid Retention
The PPARγ agonist-induced ﬂuid retention results in
plasma volume expansion (often measured as a decrease
in hematocrit) and peripheral edema [5]. The excess ﬂuid
retention is relatively resistant to diuretics [4, 5]. In a
diuretic comparison study, the most promising results
were obtained with intensive therapy using an aldosterone
antagonistthathasactionsinthedistaltubule/collectingduct
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The propensity to cause ﬂuid retention is serious enough
toraisequestionsaboutthecontinueduseoftheseagonists—
particularly in a marginal patient population. Rat studies
have indicated that the increased plasma volume can cause
relatively rapid cardiac remodeling, even in healthy animals
[7]. A recent high-proﬁle meta-analysis has indicated that
Avandia (rosiglitazone) increases the risk of death from
cardiovascular disease [8], while other studies have observed
beneﬁcial eﬀects of TZDs on major cardiovascular events in
humans as well as protection against ischemia-reperfusion
injury and reduction of myocardial infarct size in animal
models [9–11]. Additional data are required to ascertain
the risk/beneﬁt relationships of TZD therapy for patients
with cardiovascular risk factors but it is clear that edema
is an undesirable side eﬀect. Eﬀective therapy to limit ﬂuid
retention would increase the usefulness of this class of
compounds and is necessary if they are to be used as a
prophylactic treatment to delay the progression of metabolic
syndrome to type 2 diabetes.
3. Blood Pressure
Modest decreases in blood pressure during treatment with
PPARγ agonists are a consistent ﬁnding in studies conducted
in normal, diabetic, and hypertension-prone rodents and
humans (see [1]). The eﬀect, when measured continuously
in rodents, is rapid and usually manifested within 12–24
hours of the initial dosing [7, 12]. Is this a secondary
side eﬀect of the drugs per se or does this observation
indicate that the receptor is important in maintaining a
normal blood pressure? An experiment of nature indicates
thelatter. Barroso et al.characterizedraredominant negative
mutations in the human peroxisome proliferator activated
receptor γ. As expected, these patients have insulin resistance
and diabetes mellitus. Interestingly, the patients also have
severe hypertension that is diﬃcult to control [13]. Thus,
the data indicate that loss of the receptor leads to severe
increases in blood pressure and activation of the receptor as
seen in PPARγ agonist therapy causes a decrease in blood
pressure.
4. Site of Action
There is general consensus that the change in blood pressure
is likely due to a combination of renal and vascular eﬀects.
This contention is underlined by the observations that TZDs
simultaneously increase ﬂuid retention and decrease blood
pressure. Assuming normal cardiac function, it is hard to
imagine a scenerio where plasma volume expansion leads to
a decrease in blood pressure without a substantial change in
the vasculature.
PPARγ regulation in the vasculature is complex and may
exert actions on both endothelial and smooth muscle cell
function. Eﬀects on the multiple parameters of vascular
function have been recently elucidated using vascular cell-
type-speciﬁc PPARγ knockout mice. Animals defective in
the endothelial receptor are hypertensive, an eﬀect that
the authors linked to PPARγ regulation of nitric oxide
production in this cell type [14]. Conversely, a vascular
smooth muscle-selective PPARγ knockout mouse resulted
in an animal displaying a hypotensive phenotype [15]. The
authors have shown that the mechanism for the change
in blood pressure regulation is due to a PPARγ regulation
of β2-adrenergic receptor expression and concomitantly a
change in β-adrenergic agonist sensitivity. Wang and co-
authors used knockout mice to examine both endothelial
and vascular smooth muscle eﬀects of PPARγ and concluded
that there were distinct functions for the PPARγ in both cell
types but that the endothelial regulation was responsible for
the blood pressure lowering eﬀects of PPARγ agonists [16].
In addition, high levels of TZDs appear to increase vascular
permeabilityviaavarietyofproposedmechanismsincluding
vascular endothelial growth factor, nitric oxide, and protein
kinase C (reviewed in [17]). These recent studies highlight
the complexity of the vascular regulation. The remainder of
this paper will focus on the initial TZD-mediated changes
that are manifested in the kidney, speciﬁcally the collecting
duct.
Two separate knockout technologies were exploited to
speciﬁcally ablate the PPARγ in the renal collecting duct of
mice [18, 19]. In the absence of the collecting duct receptor,
the mice did not show the typical ﬂuid retention when
treated with clinically used TZDs. In contrast, the normal
littermates showed reduced hematocrits, and ﬂuid derived
weight gain after treatment. These studies substantiate the
notion that the collecting duct plays a primary role in the
PPARγ-mediated ﬂuid retention. Unfortunately, continuous
monitoring of blood pressure was not reported in these
studies.
5. Mechanismof Action: The ENaCHypothesis
The collecting duct knockout animal studies were the “icing
on the cake” for an emerging hypothesis to explain how
PPARγ agonists cause ﬂuid retention. The principal cells
lining the distal tubule and collecting duct are the site of hor-
monally regulated Na+ transport. These hormones regulate
whole body salt and water homeostasis and, therefore, blood
pressure. Principal cells respond to steroid (aldosterone)
and peptide (antidiuretic hormone, ADH; insulin/IGF1)
hormones with an increase in Na+ reabsorption leading to
increased plasma volume. All three hormones exert their
eﬀects via an insertion of the epithelial Na+ channel (ENaC)
into the luminal plasma membrane of the principal cells
thereby initiating the Na+ resorptive cascade [20–24]. Thus,
it is logical to hypothesize that any agent that causes salt and
water retention might have an eﬀect in the distal nephron,
speciﬁcally on ENaC. In addition, the PPARγ is expressed in
the distal tubule and collecting duct.
Studies prior to the creation of the PPARγ collecting
duct-speciﬁc knockout mice demonstrated a remarkable
degree of Na+ and ﬂuid retention and biochemical changes
consistent with ENaC activation. Song et al. found that
normal Sprague-Dawley rats fed a high dose of rosiglitazone
(94mg/kg body weight) exhibited a 22% decrease in urine
volume and a 44% decrease in Na+ excretion [12]. ChenPPAR Research 3
et al. found that GI262570, a PPARγ agonist, changed
electrolyte and water reabsorption in the distal nephron of
Sprague-Dawley rats [25]. Hong et al. [26] demonstrated
that PPARγ activation increased the cell surface expression
of the α subunit of ENaC by upregulating serum gluco-
corticoid kinase (SGK), an enzyme previously shown to
be a convergence point for hormone activation of ENaC
[27, 28]. All of these ﬁndings are consistent with a TZD
eﬀect on ENaC or pathways that regulate this Na+ channel.
Further corroboration was found in studies demonstrating
that amiloride (a speciﬁc inhibitor of ENaC) prevented
the TZD-induced increase in body weight gain in mice
[19] and the previously cited ﬁnding that an aldosterone
antagonist, which acts to supress ENaC activity, is the most
eﬀective agent for combating PPARγ agonist-induced ﬂuid
retention [6]. From all of these early studies, it appeared
that upregulation of ENaC was responsible for the PPARγ
agonist-induced salt and water retention.
In the myriad of studies that followed the initial ﬁndings,
some discrepancies began to appear. For example, not all
studies were able to demonstrate inhibition of ﬂuid retention
by amiloride. There was a lack of consistency between
studies as to which, if any, of the three ENaC subunits
was regulated by the agonists and whether SGK actually
changed in response to treatment. Nofziger et al. were unable
to reproduce the stimulation of ENaC by PPARγ agonists
in any of three well-characterized principal cell lines that
endogenously express the receptor [29]. In human and
animal studies, there did not appear to be a consensus as to
the eﬀect of TZDs on aldosterone secretion. In some studies
t h i sh o r m o n el e v e lh a sb e e nr e p o r t e dt oi n c r e a s e[ 7, 30], and
in others PPARγ agonist treatment resulted in a decreased
aldosterone level [6, 12, 18, 25].
6. Mechanismof Action:
Physiological Considerations
While the ENaC hypothesis is appealing in its simplicity,
is this the whole story? Do all of the ﬁndings correlate
with known physiological principles? First and foremost,
does the correlation between increased ﬂuid retention and
decreased blood pressure make sense, particularly when
evoking regulation via an aldosterone/ENaC mechanism?
Amiloride and aldosterone antagonists are clinically used
diuretics that inhibit ENaC activity directly or secondarily,
and lower blood pressure by decreasing Na+ and ﬂuid
retention. In the treatment of hypertension, an increase in
Na+ reabsorption via ENaC is equated with an increase in
blood pressure not a decrease as seen during PPARγ agonist
therapy.
There are some interesting experiments of nature that
can inform this issue as well. There are human mutations
in ENaC subunits that give rise to both gain-of-function
and loss-of-function in channel plasma membrane expres-
sion or activity. The gain-of-function mutations known as
Liddle’s syndrome result in severe, diuretic-resistant hyper-
tension [31]. In loss-of-function mutations, life-threatening
salt wasting, hypotension, and hyperkalemia occur during
the neonatal period [32, 33]. Based on the presentations
of these naturally occuring mutations, which alter ENaC
activity in an in vivo setting, one can conclude that it is
unlikely that PPARγ agonist stimulation of ENaC will result
in a decreased blood pressure. Thus, physiological principles
as we understand them seem inadequate to explain how
ENaC stimulation and increased ﬂuid retention correspond
to a decrease in blood pressure.
In a recent study, Vallon and colleagues [34] condition-
ally inactivated the α subunit of ENaC in the collecting
duct of mice. This technique functionally inactivates the
Na+ channel in the same area of the kidney as the previous
PPARγ depletion experiments. The mice in which collecting
duct ENaC was inactivated still demonstrated the PPARγ
agonist ﬂuid retention as observed in the control mice.
Blood pressure measurements were not reported in this
study. The authors concluded that activation of ENaC is
not the primary mechanism in the TZD-induced ﬂuid
retention.
7. Mechanismof Action:
AlternativePossibilities
If the ENaC hypothesis does not ﬁt well with known
physiological principles, are there alternative possibilities?
Putting all the data together, it does appear that one of the
sites of action for both ﬂuid retention and blood pressure
eﬀects is indeed the kidney, speciﬁcally the collecting duct.
The strongest support for this contention results from the
collecting duct-speciﬁc PPARγ knockout mice [18, 19]. If
the primary eﬀect is not manifested on ENaC, it is likely
that the observed changes in Na+ retention are secondary
consequencesinresponsetochangesinotherionﬂuxes.Such
secondary eﬀects would explain the diuretic eﬃcacy and also
the variability seen in hormonal responses and changes in
ENaC subunit abundance.
When examining other potential ion transporters, one
intriguingpossibilityisaTZD-mediatedchangeinCl
−.Diets
contain approximately equal concentrations of Na+ and Cl
−
but the movement of Na+ is considered to be of primary
importance because it is hormonally controlled. However,
there are emerging studies that suggest that control of renal
Cl
− transport can modulate blood pressure as well.
An u m b e ro fd i ﬀerent chloride channels have been
found in various segments of the renal nephron [35, 36].
Mutations in one of these channels, termed ClCK-Kb, has
been shown to predispose carriers to hypertension [37],
leading to the conclusion that this channel may be relevant
in salt sensitivity of blood pressure regulation [38]. One of
the major Cl
− channels found in the collecting duct is the
cystic ﬁbrosis transmembrane regulator (CFTR) [35]. CFTR
isimportantformaintainingﬂuidbalance,particularlyinthe
lung, as demonstrated by the loss of this channel in cystic
ﬁbrosis. While changes in the activity of Cl
− channels in
other portions of the nephron have been linked to changes
in blood pressure, a role for the CFTR Cl
− channel has yet
to be established. Tantalizingly, like ENaC, this channel is
activated by ADH and could, theoretically, be involved in4 PPAR Research
hormonal control of salt and water balance in this portion
of the nephron [35, 39, 40].
We have recently found that a variety of PPARγ agonists
inhibit ADH-stimulated Cl
− s e c r e t i o ni nac e l lc u l t u r em o d e l
of the principal cells of the cortical collecting duct. The
potency of the agonists to inhibit hormone-stimulated Cl
−
transport mirrors receptor transactivation proﬁles except
that the IC50 for the eﬀect on Cl
− transport is an order of
magnitude more sensitive. Analyses of the components of
the ADH-stimulated intracellular signaling pathway indicate
no PPARγ agonist-induced changes in any of the known
steps in the transepithelial signaling pathway. The PPARγ
agonist-induced decrease in anion secretion is the result of
a decrease in the mRNA encoding the ﬁnal eﬀector in the
pathway, the apically located CFTR Cl
− channel [40]. These
data showing that CFTR is a target for PPARγ agonists
provide new theoretical possibilities for PPARγ agonist-
induced ﬂuid retention. The data, if substantiated by in
vivo experiments, indicate that CFTR plays a role in ﬂuid
balance.
Recently,a similar PPARγ agonist-mediated eﬀectonCl
−
ﬂux has been demonstrated in mouse intestinal epithelia.
Mice fed with rosiglitazone for 8 days had reduced intestinal
forskolin-stimulated anion secretion and substantiallyinhib-
ited cholera toxin-induced intestinal ﬂuid accumulation.
Both of these processes occur via CFTR mechanisms. In the
HT29 intestinal cell line, 5-day treatment with rosiglitazone
inhibits cAMP-dependent Cl
− secretion. This decreased
secretion was accompanied by decreases in the protein
levels of CFTR, the Na+/K+/2Cl
− cotransporter that allows
basolateral inﬂux of Cl
− and in KCNQ1, which serves as a
basolateral K+ recycling channel [41].
Thus, there are data to suggest that the primary eﬀect of
PPARγ agonists on ion transporters in polarized epithelial
cells is due to a decrease in the expression of the CFTR
channel and, perhaps, in other transporters that mediate
Cl
− secretion. Exactly how this translates into simultaneous
eﬀects on ﬂuid retention and decreased blood pressure is
unknown. The theoretical possibilities range from changing
electrochemicaldrivingforcesfortransepithelialtransportto
altering ion and ﬂuid partitioning between the interstitium
and the vascular ﬂuid compartment.
8. Summary
While the mechanisms of action of the PPARγ agonists
in lowering blood pressure and causing ﬂuid retention
remain unknown, several important concepts are beginning
to emerge. The most recent data suggest that the TZDs do
not directly regulate the ENaC although changes in ENaC-
mediated Na+ transport may occur secondarily. Until the
physiological mechanisms of action leading to the TZD side
eﬀects are fully understood, drugs such as mineralocorticoid
antagonists and ENaC channel blockers may be the most
eﬀective diuretics in the treatment of PPARγ-mediated
edema. However, for development of new drug therapies
devoid of the negative side eﬀe c to fﬂ u i dr e t e n t i o n ,t h e
biochemical mechanism of action of the TZDs on renal and
vascular ion and water channels must be more thoroughly
investigated.
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